Editas Medicine Announces First Quarter 2021 Results and Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Editas Medicine (EDIT) Misses Q1 EPS by 13c, Revenues Beat
May 5, 2021 7:24 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.86), $0.13 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $5.77 million.
Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage... More
